Bio Green Med Solution, Inc.(BGMS)

Medical - Pharmaceuticals · Kuala Lumpur, LF

$0.87+0.00 (+0.18%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T13:30:44.577Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:30:44.577Z.

Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,801,926
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 3,790,000
TTM operating income · period ending 2026-06-30: -2,738,000

FMP input reference: c636d25f821ca328dde5756eba65a9b4f657646c0770229dc3782e5e279f5fe4

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BGMS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

BGMS Competitors' EV/EBIT Ratio

BGMS

Bio Green Med Solution, Inc.

Current

Market Cap

$4.80M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs BGMS

Market Cap

$4.85M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMGL

Basel Medical Group Ltd Ordinary Shares

vs BGMS

Market Cap

$5.26M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GELS

Gelteq Limited Ordinary Shares

vs BGMS

Market Cap

$4.81M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs BGMS

Market Cap

$4.63M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRMA

Dermata Therapeutics, Inc.

vs BGMS

Market Cap

$4.50M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLGN

CollPlant Biotechnologies Ltd.

vs BGMS

Market Cap

$4.40M

EV/EBIT Ratio

N/A

TTM Avg

661.60x

3Y Avg

661.60x

5Y Avg

661.60x

ERNA

Ernexa Therapeutics Inc.

vs BGMS

Market Cap

$4.49M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs BGMS

Market Cap

$5.21M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIDX

20/20 Biolabs Inc.

vs BGMS

Market Cap

$4.29M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Bio Green Med Solution, Inc. (BGMS)	$4.80M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.85M	N/A	N/A	N/A	N/A
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.26M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$4.81M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$4.63M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.50M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.40M	N/A	661.60x	661.60x	661.60x
Ernexa Therapeutics Inc. (ERNA)vs ›	$4.49M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$5.21M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.29M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

BGMS EV/EBIT Ratio Metrics

BGMS Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics